Roche’s bispecific monoclonal antibody emicizumab has produced a clinically meaningful reduction in the number of bleeds over time in younger hemophilia A patients with inhibitors to factor VIII, in interim results from the Phase III HAVEN 2 study. These complement results previously released from the HAVEN 1 study showing similar benefits in older hemophilia patients with inhibitors.
The results from HAVEN 2 are very early – the interim analysis was conducted after only 19 out of a...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)